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Summary
Glutamic acid decarboxylase (GAD) is the enzyme that synthesizes the neurotransmitter y-amino-
butyric acid (GABA) in neurons and in pancreatic (3 cells. It is a major target of autoimmunity
in StiffMan syndrome (SMS), a rare neurological disease, and in insulin-dependent diabetes mellitus.
The two GAD isoforms, GAD-65 and GAD-67, are the products of two different genes. GAD-
67 and GAD-65 are very similar to each other in amino acid sequence and differ substantially
only at their NH2-terminal region. We have investigated the reactivity of autoantibodies of 30
StiffMan syndrome patients to GAD. All patient sera contained antibodies that recognize strongly
GAD-65, but also GAD-67, when tested by immunoprecipitation on brain extracts and by
immunoprecipitation or immunocytochemistry on cells transfected with either the GAD-65 or
the GAD-67 gene. When tested by Western blotting, all patient sera selectively recognized GAD-65.
Western blot analysis of deletion mutants of GAD-65 demonstrated that autoantibodies are directed
predominantly against two regions of the GAD-65 molecule. All SMS sera strongly recognized
a fragment contained between amino acid 475 and the COOH terminus (amino acid 585). Within
this region, amino acids 475-484 and 571-585 were required for reactivity. The requirement
of these two discontinuous segments implies that the epitope is influenced by conformation.
This reactivity is similar to that displayed by the monoclonal antibody GAD 6, suggesting the
presence of a single immunodominant epitope (SMS-E1) in this region of GAD-65. In addition,
most SMS sera recognized at least one epitope (SMS-E2) in the NH2-terminal domain of
GAD-65 (amino acids 1-95). The demonstration in SMS patients of a strikingly homogeneous
humoral autoimmune response against GAD and the identification of dominant autoreactive
target regions may help to elucidate the molecular mechanisms of GAD processing and presentation
involved in GAD autoimmunity. Moreover, the reactivity reported here of GAD autoantibodies
in SMS partially differs from the reactivity of GAD autoantibodies in insulin-dependent diabetes
mellitus, suggesting a link between the pattern ofhumoral autoimmunity and the clinical condition.
T
he enzyme glutamic acid decarboxylase (GAD)' cata-
lyzes the conversion of L-glutamic acid to y-aminobutyric
acid (GABA), a major inhibitory neurotransmitter (1). GAD
is expressed in GABA-secreting neurons and in pancreatic a
cells (2, 3), which may also secrete GABA as a paracrine signal
molecule (4-6) . In addition, GAD is expressed in the testis
and in the epithelium of the fallopian tube (7, 8). GAD has
been identifiedas a dominant autoantigen in two human dis-
eases, Stiff-Man syndrome (SMS) (9, 10, 11) and insulin-
dependent diabetes mellitus (IDDM) (12). SMS is a rare neu-
' Abbreviations used in this paper. CHO, Chinese hamster ovary; GABA,
,y-aminobutyric acid; GAD, glutamic acid decarboxylase; IDDM, insulin-
dependent diabetes; Pt, patients; SMS, StiffMan syndrome; SMS-El, Stiff
Man syndrome epitope 1.
rological condition characterized by progressive rigidity of
the body musculature with superimposed painful spasms. It
is thought to result from an impairment of GABA-ergic in-
hibitory inputs to a-motor neurons (13-15) . Autoantibodies
directed against GAD (GAD-Abs) were detected in 72 of 119
SMS patients we studied. A frequent occurrence of IDDM
was observed in the GAD-Abs-positive SMS patients (10),
an observation that led to the identification of the 64-kD
antigen of IDDM as GAD (12). IDDM results from an au-
toimmune destruction of pancreatic /3 cells (16). GAD-Abs
are present in the large majority of IDDM patients at the
time of the diagnosis and are also present in a large fraction
of prediabetic patients (17, 18) .
GAD exists as two isoforms of67 and 65 kD, respectively,
commonly referred to as GAD-67 and GAD-65. The two
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been cloned and sequenced from several species (19-25). Both
proteins are expressed in the brain while their expression in
/3 cells varies among species (26, 27). GAD-67 and GAD-65
are highly conserved in evolution (97% identity between rat
and human GAD-67; 96% identity between rat and human
GAD-65) and are very similar to each other. They differ sub-
stantially only in the first 95 NHa-terminal amino acids
(-23% identity, -61% similarity), which are responsible
for the different subcellular localization of the two molecules
(28, 29). Over the remaining part of the molecule, which
contains the catalytic portion of the enzyme, they are -73%
identical and -95% similar.
Both autoantibodies of IDDM patients and of SMS pa-
tients were found to immunoprecipitate GAD-65 from pan-
creatic or brain extracts prepared in nondenaturing condi-
tions (12). However important differences were observed
between GAD-Abs in SMS and IDDM patients. In SMS,
GAD-Abs have a much higher titer than in IDDM. In addi-
tion, GAD-Abs of most SMS patients react with GAD in
Western blots, while GAD-Abs of the majority of IDDM
patients do not (12). Elucidating the autoreactive epitopes
of GAD-Abs in the two conditions represents a first step to-
wards the elucidation of molecular mechanisms of GAD au-
toimmunity and may be useful for the design of optimal di-
agnostic assays for the two diseases.
In this studywe have investigated the properties ofGAD-
Abs in a large group of SMS patients. An analysis was per-
formed on 30 of the 72 GAD-Abs positive SMS sera of our
case-load, all of which were GAD reactive in Western blots.
All sera contained antibodies that independently recognized
both GAD-65 and GAD-67 by immunoprecipitation. How-
ever, in Western blots all sera only reacted with GAD-65.
This reactivity was accounted for primarily by antibodies
directed against two regions of the GAD-65 molecule. One
(SMS-Epitope-1 [SMS-El]), encompassing the 000H-
terminal 110 amino acids represents the dominant autoanti-
genic region. The other (SMS-E2) corresponds to the NHZ-





Human sera of SMS patients
were from our collection of 72 SMS sera positive for GAD-Abs
(9-11). Control human sera were from healthy subjects. Rabbit
sera 7673 (raised against a peptide corresponding to the sequence
577-593 of rat GAD-67) and N65 (raised against peptide corre-
sponding to the sequence 4-21 of rat GAD-65) were previously
described (29). Rabbit serum9056 was raised against recombinant
mouse GAD-67 (clone 3b-3; kindly provided by Drs. Z. Katarova
and G. Szabo, Biological Research Center of the Hungarian
Academy of Sciences, Szeged, Hungary) (24). Rabbit serum 9057
was raised against ratbrain GAD-65 obtainedby affinity purification
and preparative electrophoresis. Rabbit serum K2 (30) was pur-
chased from Chemicon Intl., Inc. (Temecula, CA). The following
antibodies were generous gifts: mAb GAD 6 (from Dr. D. Gott-
lieb, Washington University School of Medicine, St. Louis, MO)
(31) and rabbit serum6799 (from Drs. Z. Katarova and G. Szabo)
(24). Synthetic peptides were synthesized at the Yale Protein Chem-
istry Facility (New Haven, CT).
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Purification ofRatBrainGAD
￿
GAD was purified from ratbrain
using a GAD 6 affinity column as previously described (31) with
some modifications. Approximately 100 g of rat brains (Pel-Freeze
Biologicals, Rogers, AZ) were homogenized in 600 ml of 10-mM
potassium phosphate buffer, pH 7.5, 0.2-mM EDTA, 1-mM
2-aminoethylisothiouronium bromide (AET), 0.2-mM pyridoxal
5-phosphate (PLP), pepstatin, aprotinin, leupeptin, antipain (each
at 4 lAg/ml; Sigma Chemical Co., St. Louis, MO), and 0.4 /AM
PMSF (buffer A) using an SDT Tissumizer (Tekmar Co., Cincin-
nati, OH) at maximum speed and clarified by centrifugation at
130,000g for 1 h at 4°C. The supernatant was loaded on an affinity
column prepared by conjugating the antibody GAD 6 to Affi-gel
10 (Bio-Rad Laboratories, Richmond, CA). The column was ex-
tensively washed with buffer A without EDTA (buffer B), and sub-
sequently with 1.0 M NaCl in buffer B. GAD was eluted with
high pH buffer (50 mM potassium phosphate, 10 mM diethyla-
mine, and 20 mM glutamic acid adjusted to pH 11), neutralized,
dialyzed against 2 mM Hepes, pH 7.4, at 4°C, concentrated by
lyophilization, resuspended in SDS-PAGE sample buffer, and run
on an 8% polyacrylamide preparative gel. The GAD-65 and GAD-
67 bands, visualized by Coomassie blue staining, were separately
excised from the gel and electroeluted with an Elutrap device
(Schleicher and Schuell, Inc., Keene, NH).
GAD-65 andGAD-67 Fusion Proteins.
￿
A full-length rat brain
GAD-65 cDNA clone was isolated as previously described (29).
A full-length rat brain GAD-67 cDNA clone was a kind gift of
Dr. D. Gottlieb (21). cDNAs encoding full-length GAD-67, full-
length GAD-65, as well as GAD-65 fragments were subdoned into
the bacterial expression vector, pmalc2 (New England Biolabs,
Beverly, MA), by using synthetic oligonucleotide primers in PCR
reactions. A specific restriction enzyme site was introduced into
each primer to facilitate subdoning into the polylinker region of
pmalc2. EcoRI and HindIII sites were added, respectively, to 5'
and 3' primers of GAD-65, and Xbal and HindIII sites to 5' and
3' primers ofGAD-67. Stop codons were engineered in the 3' primers
for those constructs missing the COON terminus. Constructs
yielded a recombinant protein composed of the maltose binding
protein (-42,000 daltons) fused to the NH2 terminus of GAD or
GAD fragment. Isopropyl O-D-thiogalactopyranoside (IPTG)-
induced Escherichia coli expressing the fusion protein were re-
suspended in SDS-PAGE sample buffer and used for Western blot
analysis. In these lysates, the fusion protein represented a major
protein band whose identity was confirmed by Western blotting,
using an antiserum directed against the maltose binding protein
(New England Biolabs). The electrophoretic mobilities of the fu-
sion proteins approximately coincided with the expected mobili-
ties based on the estimated molecular mass. However, because mo-
bility on SDS gels does not correlate absolutely with molecular
mass, constructs that proved critical in the definition of the epi-
topes were sequenced. These were H, D, E, F4, F5, and F14.
SDS-PAGEandImmunoblotting.
￿
SDS-PAGE and Western blot-
ting were performed essentially as described by Laemmli (32) and
by Towbin et al. (33). All protein samples were boiled 3 min in
SDS-PAGE sample buffer in the presence of 20 mM dithiothreitol
before loading on gels. Nitrocellulose blots were incubated in
blocking solution of 20 mM Tris, pH 7.5, 150 mM NaCl, 0.1%
(vol/vol) Tween-20, and 5% (wt/vol) dry milk (TBST/milk). All
antibody dilutions, subsequent incubations and washes were per-
formed in TBST/milk at room temperature. Primary antibodies
to be used for immunoblotting ofbacterial lysates were preadsorbed
with a Iysate of the host bacteria not expressingthe fusion protein.
Primary antibodieswere used at the following final dilutions: GAD
6, 6799 and patient sera at 1:500; 7673 at 1:250; K2 and N65 at
1:100. SMS sera and GAD 6 were followed by rabbit anti-humanor rabbit anti-mouse IgG (1:1,000 dilution), respectively . Bound
antibodies were detected by tz'I protein A (105 cpm/ml) . For quan-
titation of the integrated optical density of individual autoradio-
graphic bands, autoradiograms were scanned using the Bio Image
program on a Visage 2000 scanner (Millipore Corp ., Bedford, MA) .
Miscellaneous Procedures.
￿
The preparation of Chinese hamster
ovary (CHO) cells that stably express GAD-65 or GAD-67 was
previously reported (29) . For SDS-PAGE of these cells, SDS-PAGE
sample buffer was added directly to the incubation flasks . Prepara-
tion of Triton X-100 extracts of rat brain and of CHO cells, as
well as immunoprecipitation from such extracts, were performed
as described (5, 29) . In some cases, proteins from rat brain were
denatured bySDS and boiling before being used for immunopre-
cipitation . The postnuclear supernatant (5) was solubilized in 1%
SDS or in 1% SDS, 25mM dithiothreitol, 5 mM iodoacetamide,
and boiled for 3 min . A fivefold (wt/vol) excess of Triton X-100
was then added . Subsequently, the final concentration of this non-
ionic detergent was brought to1% by dilution with 10 mM Hepes,
pH 7.4, 150 mM NaCl, and protease inhibitors, and immunopre-
cipitation was then performed as described (5) . Double-immunoflu-
orescence was performed as described (34) . Protein concentration
was determined by the BCA reagent (Pierce, Rockford, IL) .
Results
GAD-Abs o ,fSMS Patients Recognize Selectively GAD-65
in Western Blots. The reactivity of SMS sera was first tested
by Western blotting on full-lengthGAD usingboth purified
GAD from rat brain, as well as recombinant rat GAD. We
had previously shown that SMS sera react similarly with rat
and human GAD in Western blots (9, 10) . Rat brain GAD
was purifiedby affinity chromatography using the mAbGAD
6 . As previously reported (31), this procedure results in the
purification of both GAD-65 and GAD-67 (see also Fig . 1) .
To facilitate the analysis of the reactivity of thetwo isoforms
the purified material was run on a preparativeSDS polyacryl-
amide gel and the gel regions corresponding to GAD-65 and
GAD-67 were separately excised and electroeluted. Protein
staining of electrophoretically-purified GAD-65 and GAD-
67 is shown in Fig . 1 A . Nitrocellulose strips containing
samples identical to those shown in Fig. 1A were immuno-
blotted with several anti-GAD animal sera (Fig. 1 B) andSMS
sera (Fig. 1 C) .
Rabbit serum 7673, which was raised against the 17 000H-
terminal amino acids of rat GAD-67, recognized bothGAD
isoforms (Fig . 1 B) . GAD-65 differs from GAD-67 in this
region by a single amino acid (serine 577 ofGAD-67 is replaced
by a glutamine inGAD-65) . Rabbit sera 6799 and K2, which
were raised to recombinant GAD-67 from mouse and cat,
respectively (24, 30), recognized primarily, but not exclu-
sively, GAD-67 (Fig . 1 B) . The mAb GAD 6 (Fig . 1 B) and
all 30 SMS sera only reacted with GAD-65 (Fig. 1 C and
not shown) .
Identical results were obtained when the same animal an-
tibodies andSMS sera were reacted by Western blotting with
full-length GAD-65 and GAD-67 expressed as fusion pro-
teins in bacteria (Fig. 2) or independently inCHO cells (not
shown) .
GAD-Abs ofSMS Patients Recognize Both GAD-67 and
GAD-65 by Immunoprecipitation andhmmunocytochemistry.
￿
All
SMS sera immunoprecipitated both GAD-67 and GAD-65
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Figure 1 .
￿
SMS patient sera recognize selectively GAD-65 in Western
blots of brain GAD . Coomassie blue staining of GAD-65 and GAD-67
purified by affinity chromatography and preparative electrophoresis from
brain (A). Western blot of nitrocellulose strips identical to those shown
inA with rabbit sera 7673, 6799, K2, and mAb GAD 6 (B) . Western
blot of strips identical to those shown in A with sera of SMS patients
(Pt, followed by patient code number) (C) . A slight cross-contamination
of the two isoforms is not visible by protein staining but is apparent from
the Western blots shown in B and C .
from Triton X-100 brain extracts prepared in nondenaturing
conditions (Fig . 3 A) . For comparison, immunoprecipitates
obtained with several anti-GAD and control animal antibodies
areshown in Fig. 3 B . These findings confirmed our previous
Figure 2 . SMS patient sera recognizes
selectively recombinant GAD-65 in Western
blots. Bacterial lysates expressing full-length
GAD-65 and GAD-67 were reacted by
Western blotting with rabbit serum 7673,
ahuman control serum (HCS), andthree sera
ofSMS patients (Pt, followed bypatient code
number) .Figure 3 .
￿
SMS patient sera immunoprecipitate bothGAD 65 andGAD
67 from a brain extract. Triton X-100 extracts of rat brain were immuno-
precipitatedwith sera ofSMS patients (Pt followed by patient codenumbers)
(A) and several anti-GAD animal antibodies (B). GAD present in the im-
munoprecipitates was revealed by immunoblottingwith serum 7673, which
reacts with bothGAD isoforms . Rabbit sera N65 and 9057 immunopreci-
pate selectively GAD-65 ; rabbit sera K2, and 9056 as well as mAb GAD
6 immunoprecipitate both GAD isoforms but in different relative ratios .
RCS, rabbit control serum ;MCA, mouse control ascites . Note the similar
ratio of GAD-67 to GAD-65 immunoprecipitated by all SMS sera. Pt227
is a control patient negative for GAD-Abs .
immunoprecipitation results obtained with a small group of
SMS sera (12) . The discrepancy between the reactivity dis-
played by SMS sera in Western blots and immunoprecipita-
tions may have at least two explanations . One is that SMS
sera contain antibodies that recognizeboth proteins in their
native state . The other is that SMS sera contain only anti-
bodies directed against GAD-65, but immunoprecipitate
GAD-67 because the twoproteins form heterodimers in the
brain and in the pancreas . On the other hand, two rabbit
sera, N65 and 9057, can immunoprecipitate selectivelyGAD-
65 (Fig. 3 B) . N65 was raised against a GAD-65-specific se-
quence (amino acids 4-21), and 9057 was raised against purified
ratbrain GAD-65 . Note that two rabbit sera (9056 and K2)
raised against GAD-67 immunoprecipitated both isoforms
but with an higher relative ratio GAD-67/GAD-65compared
with SMS sera and to GAD6 .
Establishing whether autoantibodies recognize GAD-67
as well as GAD-65 is ofconsiderable interest for the elucida-
tion of mechanisms of autoimmunity. Thereforewe addressed
this question in more detail . SMS sera were tested for their
capacity to recognize in immunoprecipitation experiments
GAD-65 or GAD-67 independently expressed by transfec-
tion inCHO cells . Fig . 4 shows results of immunoprecipita-
tion performed on Triton X-100 extracts ofCHO cells ex-
pressing either GAD-65 (GAD-65-CHO cells) or GAD-67
(GAD-67-CHO cells) with animal and human sera . In each
gel, thelowerband represents immunoglobulin heavychain.
The ability offourSMS sera to immunoprecipitate both pro-
teins is shown by the figure. Identical results were obtained
with all the other SMS sera tested. Therefore, SMS sera do
recognize both GAD-65 and GAD-67 and their failure to
react withGAD-67 in Western blots may be due to irrevers-
ible loss ofGAD 67 epitope(s) by SDS-induceddenaturation.
In fact, SMS sera immunoprecipitated only GAD-65 when
tested againstbrain extracts that had been denatured by SDS
and boiled before immunoprecipitation (not shown) .
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Figure 4.
￿
SMS patient sera immunoprecipitate both GAD-65 andGAD-
67 from CHO cells independently transfected with the two GAD iso-
forms . Triton X-100 extracts of cells that stably express either GAD-65
or GAD-67 were immunoprecipitated with SMS sera and anti-GAD an-
imal antibodies. GAD present in the immunoprecipitates was revealed by
immunoblotting with rabbit serum 7673, which recognizes both GAD
isoforms . The GAD bands are indicated by arrowheads. The heavy band
just below GAD in each panel represents the heavy chain of IgG . Anti-
body and patients codes are indicated at the top of each lane .
Immunoprecipitates obtained with several animal anti-GAD
antibodies are shown in Fig. 4 B as controls . Rabbit serum
9056 immunoprecipitated both GAD-67 and GAD-65 . Similar
results were obtained with serum K2 (not shown) . How-
ever, rabbit sera 9057 and N65 as well as mAbGAD 6 im-
munoprecipitated GAD only from GAD-65-CHO cells,
confirming their specificity forGAD-65 . Thecapacity ofGAD
6 to immunoprecipitate bothGADisoforms from brain Triton
X-100 extracts supports the concept that GAD-65/GAD-67
heterodimers can be precipitated by GAD-65-specific sera .
When GAD 6 was tested against brain extracts pretreated
with SDS and boiling, only GAD-65 was immunoprecipi-
tated (not shown) .Apossible explanation for the lack ofGAD-
67 in immunoprecipitates produced by sera N65 and 9057
(Fig . 3 B) is that the epitope(s) recognized by these antibodies
is (are) hidden in theheterodimer. As discussed below, serum
9057 reacts selectively with the region ofGAD-65 that con-
tains the peptide recognized by N65.
Immunocytochemistry of formaldehyde-fixed transfected
CHO cells with thesame set ofhuman and animal antibodies
confirmed immunoprecipitation results. SMS sera stained both
GAD-67-andGAD-65-CHO cells, andproduced the staining
pattern expected (29) for the two GAD isoforms (Fig. 5),
i.e ., a diffuse and a particulate pattern respectively. Sera N65
and 9057 as well as mAbGAD 6 stained only GAD-65-CHOFigure 5 .
￿
SMS sera stain both GAD 65 and GAD 67 in formaldehyde-fixed transfected CHO cells. GAD-65 and GAD-67 CHO cells, as well as
wild typeCHO cells, were stained by immunofluorescence with the serum of SMS patient 481 and counterstained with mAb GAD 6 and rabbit serum
6799 (which recognizes both isoforms) . (Calibration bar, 31 gm) .
cells, while sera 9056 and K2 stained GAD-67 CHO cells
more intensely than GAD-65-CHO cells (not shown) .
Identification o,fTwoDominant Autoreactive Regions in GAD-
65. The property of GAD-Abs to react with GAD-65 in
Western blots is a characteristic of the large majority ofSMS
sera, but is only seldomly observed in IDDM sera (12, 35,
36) . It was of interest to identify the GAD-65 autoepitope(s)
responsible for this reactivity. SMS sera were tested by Western
blotting against deletion mutants of GAD-65 expressed as
fusion proteins in bacteria . Initial experiments carried out
with a few SMS sera on a variety of GAD-65 fragments in
which progressively longer portions of the NH2-terminal re-
gion had been deleted, demonstrated that autoantibodies of
different patients had similar patterns of reactivity and were
primarily directed against the COOH-terminal region . There-
fore immunoreactivity of the COON-terminal region was
mapped further.
Several deletion mutants ofGAD-65 were constructed as
fusion proteins (Figs. 6 D and 7 D, and not shown), and
lysates containing approximately equal amount of fusion pro-
teins (Figs . 6 A and 7 A) were analyzed by Western blots
with animal GAD antibodies (Figs . 6 B and 7 B) and with
all 30 human SMS sera (Figs. 6 C and 7 C, Table 1, and not
shown) .
As expected, rabbit serum 7673 directed against the COOH
terminus ofboth GAD-67 and GAD-65 labeled all GAD-65




confirming the identity of the constructs (Figs . 6 B and 7
B) . Deletion of the last four amino acids was sufficient to
greatly reduce labeling by this serum. All SMS sera reacted
very strongly with a fragment (fragment F), composed of
the region between amino acid 445 and theCOOH terminus
(amino acid 585) (Fig. 6 C) . Reaction with this fragment
appeared to be even stronger than with full-length GAD-65,
as if the NH2-terminal region of the molecule interfered
with GAD-Ab binding to this GAD-65 region (Fig. 7 C) .
Progressive deletions of up to 30 amino acids residues from
the NH2-terminal side of this fragment (fragments F2, F3,
and F4) did not significantly change its reactivity (Figs . 6
C and 7 C) . An additional 10-amino acid deletion at the
NH2 terminus of F4 (amino acids 475-585) to create frag-
ment F5 (amino acids 484-585) drastically reduced im-
munoreactivity (Figs . 6 C and 7 C) . This suggested that the
epitope lies between amino acids 475 and 484 .
However, quite unexpectedly, fragment F1 (amino acids
445-515) resulting from a COOH-terminal deletion offrag-
ment F, was also unreactive (Fig . 6 C) . A similar reactivity
towards fragment F4, but not towards fragments F5 and F1,
was observed with the mAb GAD 6 (Figs . 6 B and 7 B) .
Further deletion analysis ofthe COON-terminal side offrag-
ment F4 (Fig. 7 C) indicated that removal of the last 14 amino
acids (fragment F12 ; amino acids 475-571) was sufficient to
abolish reactivity with all SMS sera and with GAD 6 .
Moreover, deletion of only the last four amino acids (frag-Figure 6 .
￿
Identification of the COON-terminal GAD epitope in SMS
sera . Deletion mutants of GAD-65 were constructed as fusion proteins
and lysates containingapproximatelyequal amounts offusion proteins were
analyzed by SDS-PAGE and Westernblotting . The boundaries of the frag-
ments are shown schematically inD . Numbers represent amino acid posi-
tion in GAD-65 . (A) Protein staining ofbacterial lysates . Note that the
fusion proteins appear as major protein bands. (B) and (C) Immunoblots
of gels identical to those inA . Blots were incubated with serum 7673,
with mAb GAD 6 (A), and with several SMS patient sera (C) .
ment F14, amino acids 475-581) produced a major loss of
reactivity in the case of 14 SMS sera and GAD 6, as well
as a complete loss of reactivity in the other 16 SMS sera (see-
Fig . 7 and Table 1) . Reactivity of fragment F14 was similar
to that of fragmentM (amino acids 190-581), and reactivity
offragment F12 was comparable to that offragmentN (amino
acids 190-571), demonstrating that most of the immunoreac-
tivity present in the COOH-terminal two-thirds of the mol-
ecule is attributable to an epitope contained in fragment F4
(henceforth defined as SMS-Epitope 1 = SMS-E1) . In only
a few patients a weak immunoreactivity was observed in frag-
ment E (amino acids 190-375) which did not contain SMS-
El . In these cases, fragments M and N were slightly more
immunoreactive than fragments F12 and F14 (i .e ., patient 338
in Fig. 7 C) . The importance of the COOH terminus of
GAD-65 to the reactivity of SMS sera was emphasized by
the observation that deletion of the last 14 COOH-terminal
amino acids from full-lengthGAD resulted in a dramatic loss
of reactivity of those sera that reacted exclusively or almost
exclusively with SMS-E1 (not shown) . In summary, SMS-E1
is contained within theCOON-terminal 110 amino acids of
The retention of some reactivity towards COOH-ter-
minal-deleted GAD-65 constructs implied the presence of
some immunoreactivity also in the N142-terminal region of
GAD-65 . This was confirmed by analyzing the reactivity of
SMS sera with NH2-terminal GAD-65 fragments (Fig. 7 C
and Table 1) . In all cases intensity ofimmunoreactivity against
fragment D (amino acids 1-190) was very similar to im-
munoreactivity,against fragment H (amino acids 1-95), sug-
gesting that the NH2-terminal autoantigenic region (SMS-
Epitope 2 = SMS-E2) is contained within amino acids 1-95,
i .e ., the region of diversity between GAD-65 and GAD-67 .
Rabbit serum N65 (Fig. 7 B), raised against an NH2-ter-
minal GAD-65-specific region (amino acids 4-21), recognized
selectively, and with equal intensity, fragments D and H . A
similar selective reactivity with fragmentsD andH was ob-
served with serum 9057 raised against rat brainGAD-65 (not
shown) suggesting that this serum as well is primarily directed
against its N142-terminal 95 amino acids .
Table 1 summarizes the reactivity of the 30SMS sera against
the fragments that define epitopes SMS-El and SMS-E2 as
determined by scanning of the corresponding autoradiograms.
The table clearly shows the predominant reactivity against
SMS-E1 .
Discussion
In this study we have investigated the antigenic targets of
GAD-Abs in SMS. A remarkable degree of similarity in the
immune response of these patients was observed . Antibodies
recognize bothGAD isoforms, but selectively recognize GAD-
65 after SDS-induced denaturation . Within GAD-65, two
main autoreactive regions which are located in the COOH-
terminal and N142-terminal regions, respectively, were iden-
tified . The COOH-terminal region contains the main au-
toreactive epitope (SMS-E1) which is recognized by all SMS
sera .
The ability of SMS sera to immunoprecipitate GAD-67
in addition to GAD-65 from brain extracts prepared in non-
denaturing conditions confirms our previous results (12) and
extends them to a large group ofSMS sera . In those previous
results it could not be discerned whether GAD-67 was
coprecipitated with GAD-65 simply due to heterodimer for-
mation (as it is probably the case for the mAb GAD 6 [this
study]) or due to the presence ofantibodies that directly recog-
nize GAD-67 . This study conclusively establishes that both
proteins are recognized by SMS GAD-Abs.
The GAD-65 domain, which was recognized in Western
blots by all SMS sera tested, and which accounted for most
of the immunoreactivity in nearly all of them, was mapped
to the COOH-terminal 110 amino acids of GAD-65 (frag-
ment F4), i.e., a region where GAD-65 and GAD-67 are
similar to each other (75% identical, 81% similar) (20-23) .
Short deletions at either the NH2-terminal or 000H-
terminal region o£ fragment F4 were sufficient to abolish re-
activity. Fragment F4 is recognized similarly by the mAb
GAD 6 suggesting that GAD 6 and SMS GAD-Abs recog-
nize a single immunodominant epitope (SMS-E1) in this frag
GAD-65 and both amino acid segments 475-484 and 571-585
￿
ment. The observation thatCOON-terminal deletions ofonly
are crucially required for reactivity.
￿
14 amino acids completely abolish reactivity of most SMS
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￿
Reactivity of SMS sera withGAD fragments expressed as fusion proteins. (A) Protein staining of bacterial lysates expressing the constructs
shown in D . In all lanes the fusion protein is represented by a major band . B andC show Western blots of gels identical to that shown in A labeled
with animal antibodies (B) and sera of SMS patients (C) as indicated on each gel .
sera, while few of these sera as well as GAD 6 are still par-
tially reactive after COOH-terminal deletions of only four
amino acids, suggests some heterogeneity in the binding prop-
erties of different antibodies to this epitope. The possibility
that our results may be due to abnormal folding of fragment
F4 due to its being part of a fusion protein seems unlikely,
because COOH-terminal deletions had similar effects on F4,
on GAD constructs that included much longer portions of
the molecule, and on full-length GAD-65 .
The requirement oftwo amino acid segments that are sepa-
rated by -100 amino acids for the reactivity of fragment F4
may have at least two explanations. One is that epitope SMS-
El is conformational and requires the two amino acid seg-
ments to be in close proximity for reactivity with SMS sera .
The renaturation of such an epitope so that it would be de-
tected by Western blot is consistent with the partial folding
and renaturation ofother proteins afterSDS-PAGE and transfer
to nitrocellulose (37, 38) . Alternatively, the antibodies recog-




comes cryptic following short deletions from either side of
the fragment . Possibly, either of thetwo amino acid stretches
that are crucially required for the reactivity of fragment F4
(amino acids 475-484 and 571-585) may be part of the epi-
tope. To test this possibility we examined whether reactivity
ofSMS sera and of the mAb GAD 6 with the epitope SMS-
El was abolished by their preincubation with synthetic pep-
tides . Neither a peptide represented by amino acids 473-486
ofGAD-65, nor the 17-mer peptide used to raise rabbit serum
7673 (which contains amino acids 571-585 ofGAD-65), abol-
ished or reduced the reactivity of SMS sera or GAD 6 on
immunoblots. As expected, the latter peptide completely abol-
ished reactivity of serum 7673 (not shown) . Lack of inhibi-
tion was also observed when similar peptide competition ex-
periments were performed by immunocytochemistry on
GAD-65-CHO cells and by Western blotting on rat brain,
i .e ., on full-length GAD-65 (our unpublished observations) .
A second autoantigenic region of GAD-65 was mapped
to the NHa-terminal portion of the molecule (epitope SMS-Table 1.
￿
Reactivity of SMS-Abs with GAD-65 Fragments
The table was constructed by analyzing autoradiograms like those shown in Fig. 7 C. Individual autoradiographic bands corresponding to GAD-65
fragments and full-length GAD-65 were quantified as described in Materials and Methods. The ratio of the OD of each fragment to the OD of
full-length GAD-65 wascalculated. Each ratio is represented by the filled-in blackareas. Thus, the size oftheblackarea directly reflects thereactivity
of each GAD fragment. Fragment boundaries are shown in Fig. 7 D.
E2), which is quite divergent in amino acid composition from
GAD-67 (20-23). Whether SMS-E2 represents the collec-
tion of several epitopes remains to be elucidated. In the case
of most SMS sera, reactivity with this region is much less
intense than reactivity with SMS-E1.
Our study demonstrates some important similarities be-
tween the humoral response to GAD in SMS and IDDM.
In IDDM as well, GAD-Abs are primarily directed against
GAD-65 (35, 36, 39-41) and predominantly against the re-
gion of greatest similarity between GAD-65 and GAD-67
(12, 36, 42-45). Moreover, the COOH terminus of GAD-
65, which strongly influences SMS reactivity towards GAD,
is also critical for reactivity of several IDDM antibodies (36,
46). In spite of these similarities, GAD-Abs found in SMS
and IDDM display potentially important differences. GAD-
Abs are present in SMS sera with a much higher titer (12).
Furthermore, and possibly related to the titer, the majority
of IDDM sera are nonreactive, or only weakly reactive, in
Western blots and in immunocytochemistry of fixed brain
and pancreas (10, 12, 46, 47). Recently, the identification of
the autoepitopes recognizedin GAD-65 by five human mAbs
derived from lymphocytes of one newly diagnosed diabetic
patient was reported (36). Three epitopes, which were all
localized in the middle and COOH-terminal region, were
identified. Two ofthese epitopes are crucially dependent upon
distant regions of the molecule, not reactive in Western blots,
and require either the middle and COOH-terminal domain
or a middle domain ofGAD-65. The reactivityof the human
mAbs that recognize these epitopes appeared to reflect the
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reactivity of several IDDM patients. The third epitope was
defined as a linear epitope located close to the COOH ter-
minus. A similar GAD-65 COOH-terminal linear epitope
recognized by a few IDDM sera was also reported by Mouch
et al. (46) . None of these epitopes appear to coincide with
the epitope SMS-E1 identified by us.
Thesedifferences are not likely to be accounted for by differ-
ences between human (36, 46) and rat (this study) GAD,
because rat and human GAD react equally well with SMS
sera (9, 10) and because the COOH-terminal region ofGAD-
65 (fragment F4) is almost identical in rat and human (97%
identity and 100% similarity). From the data shown by
Richter et al. (36) it cannot be excluded that the 000H-
terminal linear epitope might coincide with epitope SMS-E1
because this epitope is recognized by Western blot, is con-
tained within amino acids 423-585, and is disrupted by
COOH-terminal deletions. However, only a few IDDM an-
tibodies appear to recognize this epitope.
Our findings do not exclude the possibility that sera of
SMS patients might contain autoantibodies similar to those
present in IDDM in addition to the dominant antibodies in-
vestigated in this study. The epitope mapping performed in
this study was aimed at characterizing the autoantibodies that
react with GAD even after SDS denaturation, i.e., the anti-
bodies characteristic of SMS.
The different reactivity of autoantibodies in IDDM and
SMS is intriguing. Such a difference suggests a possible link
between epitope specificity of the autoantibodies and clinical
condition. The difference in humoral autoimmunity towards





METMGAD in SMS and IDDM may correlate with the fact that
IDDM, when present in SMS patients, hasusu4y a late onset
(reference 11 and our unpublished observations). It was re-
ported that the epitope specificity of the antibodies that in-
ternalize a protein in an antigen-presenting cell may affect
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